Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008657:Metabolic Clearance Rate; D008874:Midazolam / Q000493:pharmacokinetics*; D010641:Phenotype; D011110:Polymorphism, Genetic
D014151:Anti-Anxiety Agents; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D008874:Midazolam